Sudeep Pharma Ltd. (SUDEEPPHRM) — Tipsheet

Sudeep Pharma's Nandesari plant is delayed. Working capital is spiking.

Tipsheet Editorial — Fri, 22 May 2026 12:08:12 GMT

Revenue grew 27.9% to ₹642.6 cr, but the working-capital cycle has blown out to 213 days. A delayed greenfield plant adds to the pressure.

What’s new

Nandesari greenfield commissioning delayed due to LPG and energy shortages.
Working capital days jumped to 213 from 184 last year.
Battery materials Phase 1 targeted for April 2027; 700 MT in orders so far.

Why it matters

The top-line growth is solid, but the balance sheet is deteriorating. The 29-day increase in working capital ties up cash just as the company funds a delayed expansion. Management's margin recovery target of 37-38% by FY27-28 now hinges on resolving the energy shortage and scaling a nascent battery business.

What we’re watching

Revised timeline for the Nandesari plant once energy supply is secured.
Whether the battery materials ramp can hit 2,500 MT in FY27.
Management's plan to reduce the 213-day working capital cycle.

The full read

Sudeep Pharma's top line grew. Revenue rose 27.9% to ₹642.6 crore in FY26, and profit climbed 25.6% to ₹174.3 crore. The problem is on the balance sheet. Working capital days have ballooned to 213 from 184, tying up cash just as the company waits for its new Nandesari plant to come online. That greenfield project is delayed by LPG and energy shortages. Management is still pointing to a 37-38% EBITDA margin by FY27-28. Hitting that number depends on the plant running and the battery materials business scaling. Phase 1 of that business is on track for April 2027, with 2,500 MT targeted for the year. So far, orders for 700 MT are in hand from 42 customers. The growth story is real, but the working-capital spike and plant delay make the path to those margins rockier.

Primary source: BSE · NSE

Sudeep Pharma FY26: Revenue up 28%, PAT at ₹174 cr

Tipsheet Editorial — Thu, 21 May 2026 16:21:55 GMT

Speciality ingredients segment drives strong performance; company recommends ₹1.50 per share final dividend.

What’s new

Revenue up 28% YoY to ₹642 cr; PAT up 26% to ₹174 cr.
Board recommends final dividend of ₹1.50 per share.
Strong show from speciality ingredients and NSS Ireland acquisition.

Why it matters

The growth is solid, but largely anticipated from prior quarterly updates. The dividend signals management confidence in cash flows.

What we’re watching

Q1 FY27 performance in speciality ingredients.
Further margin trends amid input cost volatility.
Integration benefits from NSS Ireland.

The full read

Sudeep Pharma closed FY26 with consolidated revenue of ₹642 crore, up 28% year-on-year, and PAT of ₹174 crore, up 26%. The speciality ingredients segment and the NSS Ireland acquisition drove the growth. The board recommended a final dividend of ₹1.50 per share. While the numbers are strong, they were largely in line with market expectations built from quarterly updates. The focus now shifts to sustaining momentum in FY27 and realising further synergies from the recent acquisition.

Primary source: BSE · NSE

Sudeep Pharma wraps FY26 with 28% revenue growth, 26% PAT jump

Tipsheet Editorial — Thu, 21 May 2026 16:07:00 GMT

Audited annual numbers confirm strong speciality ingredients demand and NSS Ireland contribution; final dividend of ₹1.50 per share recommended.

What’s new

Revenue up ~28% YoY to ₹642 cr; PAT up ~26% to ₹174 cr.
Board recommends final dividend of ₹1.50 per share.
Speciality ingredients segment and NSS Ireland acquisition drove performance.

Why it matters

The numbers are strong, but this is a routine annual filing — the trajectory was already signalled in prior quarterly updates. The dividend is a modest return of capital. What matters for next year is whether the speciality ingredients run-rate can sustain.

What we’re watching

Full-year management commentary on demand visibility in speciality ingredients.
NSS Ireland integration progress and margin contribution.
Capex plan for FY27.

The full read

Sudeep Pharma closed FY26 with consolidated revenue of ₹642 crore, up 28%, and PAT of ₹174 crore, up 26%. The speciality ingredients segment and the NSS Ireland buy both pulled their weight — the same factors that drove the quarterly beats. The board also recommended a ₹1.50 final dividend. This is a clean annual filing, but nothing here is new: the trajectory was visible after Q3. The real question is whether the growth levers — speciality demand, Ireland capacity — have room to run, or whether FY27 starts on a tougher comp.

Primary source: BSE · NSE